Literature DB >> 33145597

Cutaneous leishmaniasis and health-related quality of life in returning travellers to the UK.

Emilia Peleva1, Stephen L Walker1,2,3.   

Abstract

Entities:  

Keywords:  cutaneous leishmaniasis; health-related quality of life; travelers

Mesh:

Year:  2020        PMID: 33145597      PMCID: PMC7883819          DOI: 10.1093/jtm/taaa188

Source DB:  PubMed          Journal:  J Travel Med        ISSN: 1195-1982            Impact factor:   8.490


× No keyword cloud information.
Cutaneous leishmaniasis (CL) is associated with psychological morbidity and reduced health-related quality of life (HRQoL) in endemic countries. Although CL is also reported in travellers,, there is little information on the impact of CL on HRQoL in this population. The Dermatology Life Quality Index (DLQI) questionnaire was used to measure the impact on CL on HRQoL in returning travellers. The DLQI is a widely used questionnaire in dermatology, comprising 10 questions on symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment. Individuals rate the impact of their dermatological condition over the past week as ‘not at all’, ‘a little’, ‘a lot’ or ‘very much’ for each domain. The scores to each question are added, giving a total score from 0 to 30 (maximum impairment of quality of life). We conducted a retrospective cohort study of returning travellers diagnosed with CL seen at the Hospital for Tropical Diseases, London, UK, between 1 March 2018 and 30 June 2020. Patient demographics, disease characteristics and DLQI scores were summarized using descriptive statistics. Diagnosis was confirmed using skin biopsy, with visualization of amastigotes by microscopy-culture and/or polymerase chain reaction (PCR). We excluded individuals with mucosal or mucocutaneous leishmaniasis. Fifty-eight individuals with CL were eligible for inclusion. The majority were male (67%) and their age ranged between 2 to 76 years [median 37.0 years, interquartile range (IQR) 29.5]. No individuals were human immunodeficiency virus infected but one patient was immunosuppressed. The majority of individuals (n = 39, 67%) had a single lesion, 10 (17%) had two lesions and nine (16%) had three or more lesions. Lesions were distributed on the upper limb (n = 22, 38%), lower limb (n = 22, 38%), head and neck (n = 19, 33%), and other sites (n = 5, 9%). The size of skin lesions ranged between 0.5 cm to 11 cm. The causative species identified using PCR were L. Viannia subgenus in 32 individuals (55%), L. donovani complex in 12 (21%), L. major in eight individuals, L. mexicana in two, L. tropica in two and unknown species in two. The likely regions of acquisition were the Americas (n = 35, 60%), Europe (n = 10), Middle East (n = 8), Africa (n = 4) and South Asia (n = 1). DLQI data were available for 46 adults (79%). The median age was 37.0 years (IQR 29.5) and 63% were male. The mean total DLQI score was 7.3 (SD 4.6, minimum 0, maximum 20), corresponding to a moderate effect on HRQoL. Of these, the disease had no effect on quality of life in four individuals (9%), a small effect in 13 (28%), moderate effect in 18 (39%), and very large effect in 11 (24%). The highest effects were observed on the physical symptoms and feelings, work and school, and leisure domains. The lowest effects were in the daily activities and personal relationships domains. No significant difference was observed with respect to age, gender, size or number of lesions present. This may be due to the small numbers in this cohort. In the present study, 63% of patients reported a moderate or higher impact on their quality of life. These results are similar to data from endemic countries. Studies in Brazil and Iran found that 70% and 43% of CL patients, respectively, had a moderate or high impact on their HRQoL using the DLQI., The ‘symptoms and feelings’ and ‘work and school’ domains were the most affected, as in our study., A case-control study in Turkey showed higher levels of depression and anxiety and lower quality of life in patients with CL compared to controls. Lesions and scars on visible areas, such as the face and hands, and in younger patients, seem to lead to a greater negative impact., Ulcerated lesions were associated with greater effect on HRQoL. Our small retrospective study suggests that CL diagnosed in non-endemic settings is associated with a similar reduction in HRQoL to that reported in affected individuals in endemic settings. However, further work is required to examine the long-term impact of CL on HRQoL in both types of settings particularly where access to timely and effective therapy is difficult.

Authors’ contributions

EP did the literature search, design, data analysis and manuscript writing. SW did the literature search, design and manuscript writing.

Conflict of interest

None declared.
  8 in total

1.  Translating the science of quality of life into practice: What do dermatology life quality index scores mean?

Authors:  Yan Hongbo; Charles L Thomas; Michael A Harrison; M Sam Salek; Andrew Y Finlay
Journal:  J Invest Dermatol       Date:  2005-10       Impact factor: 8.551

2.  Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

Authors:  A Y Finlay; G K Khan
Journal:  Clin Exp Dermatol       Date:  1994-05       Impact factor: 3.470

3.  Quality of life in patients with cutaneous leishmaniasis.

Authors:  Behrooze Vares; Mina Mohseni; Amireh Heshmatkhah; Saeideh Farjzadeh; Hossein Safizadeh; Simin Shamsi-Meymandi; Zahra Rahnama; Leila Reghabatpour; Omid Fathi
Journal:  Arch Iran Med       Date:  2013-08       Impact factor: 1.354

4.  Assessment of the quality of life of patients with cutaneous leishmaniasis in Belo Horizonte, Brazil, 2009-2010. A pilot study.

Authors:  Antonio Carlos de Castro Toledo; Rosiana Estéfane da Silva; Rose Ferraz Carmo; Thaís Alves Amaral; Zélia Maria Profeta Luz; Ana Rabello
Journal:  Trans R Soc Trop Med Hyg       Date:  2013-03-08       Impact factor: 2.184

Review 5.  LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014.

Authors:  Johannes Blum; Pierre Buffet; Leo Visser; Gundel Harms; Mark S Bailey; Eric Caumes; Jan Clerinx; Pieter P A M van Thiel; Gloria Morizot; Christoph Hatz; Thomas P C Dorlo; Diana N J Lockwood
Journal:  J Travel Med       Date:  2014 Mar-Apr       Impact factor: 8.490

6.  The psychological impact of cutaneous leishmaniasis.

Authors:  M Yanik; M S Gurel; Z Simsek; M Kati
Journal:  Clin Exp Dermatol       Date:  2004-09       Impact factor: 3.470

7.  Cutaneous and mucocutaneous leishmaniasis in travellers and migrants: a 20-year GeoSentinel Surveillance Network analysis.

Authors:  Andrea K Boggild; Eric Caumes; Martin P Grobusch; Eli Schwartz; Noreen A Hynes; Michael Libman; Bradley A Connor; Sumontra Chakrabarti; Philippe Parola; Jay S Keystone; Theodore Nash; Adrienne J Showler; Mirjam Schunk; Hilmir Asgeirsson; Davidson H Hamer; Kevin C Kain
Journal:  J Travel Med       Date:  2019-12-23       Impact factor: 8.490

8.  The impact of leishmaniasis on mental health and psychosocial well-being: A systematic review.

Authors:  Malini Pires; Barry Wright; Paul M Kaye; Virgínia da Conceição; Rachel C Churchill
Journal:  PLoS One       Date:  2019-10-17       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.